FDA Expands Approval of Remdesivir for Pediatric Patients
The US FDA expanded the approval of remdesivir (Veklury, Gilead Sciences) to include pediatric patients 28 days of age and older weighing at least 3 kg with positive results of direct SARS-CoV-2 viral testing.